Zahra Beyzaei1, Bita Geramizadeh1,2, Zahra Bagheri3, Sara Karimzadeh4, Alireza Shojazadeh5. 1. Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 2. Department of Pathology, Medical School of Shiraz University, Shiraz University of Medical Sciences, Shiraz, Iran. 3. Department of Biostatistics, Shiraz University of Medical Sciences, Shiraz, Iran. 4. Shiraz Medical School Library, Shiraz University of Medical Sciences, Shiraz, Iran. 5. Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
Background: The impact of de novo anti-HLA donor-specific alloantibodies (DSA) which develop after long-term liver transplantation (LT) remains controversial and unclear. The aim of this study was to investigate the role of de novo DSAs on the outcome in LT. Methods: We did a systematic review and meta-analysis of observational studies published until Dec 31, 2019, that reported de novo DSA outcome data (≥1 year of follow-up) after liver transplant. A literature search in the MEDLINE/PubMed, EMBASE, Cochrane Library, Scopus and Web of Science Core Collection databases was performed. Results: Of 5,325 studies identified, 15 fulfilled our inclusion criteria. The studies which reported 2016 liver transplant recipients with de novo DSAs showed an increased complication risk, i.e. graft loss and chronic rejection (OR 3.61; 95% CI 1.94-6.71, P < 0.001; I2 58.19%), and allograft rejection alone (OR 6.43; 95% CI: 3.17-13.04; P < 0.001; I2 49.77%); they were compared to patients without de novo DSAs. The association between de novo DSAs and overall outcome failure was consistent across all subgroups and sensitivity analysis. Conclusions: Our study suggested that de novo DSAs had a significant deleterious impact on the liver transplant risk of rejection. The routine detection of de novo DSAs may be beneficial as noninvasive biomarker-guided risk stratification.
Background: The impact of de novo anti-HLA donor-specific alloantibodies (DSA) which develop after long-term liver transplantation (LT) remains controversial and unclear. The aim of this study was to investigate the role of de novo DSAs on the outcome in LT. Methods: We did a systematic review and meta-analysis of observational studies published until Dec 31, 2019, that reported de novo DSA outcome data (≥1 year of follow-up) after liver transplant. A literature search in the MEDLINE/PubMed, EMBASE, Cochrane Library, Scopus and Web of Science Core Collection databases was performed. Results: Of 5,325 studies identified, 15 fulfilled our inclusion criteria. The studies which reported 2016 liver transplant recipients with de novo DSAs showed an increased complication risk, i.e. graft loss and chronic rejection (OR 3.61; 95% CI 1.94-6.71, P < 0.001; I2 58.19%), and allograft rejection alone (OR 6.43; 95% CI: 3.17-13.04; P < 0.001; I2 49.77%); they were compared to patients without de novo DSAs. The association between de novo DSAs and overall outcome failure was consistent across all subgroups and sensitivity analysis. Conclusions: Our study suggested that de novo DSAs had a significant deleterious impact on the liver transplant risk of rejection. The routine detection of de novo DSAs may be beneficial as noninvasive biomarker-guided risk stratification.
Authors: Colin H Wilson; Kosh Agarwal; Vaughan Carter; Alastair D Burt; Stefan Hübscher; David Talbot; Brian C Jaques; Derek M Manas Journal: Transplantation Date: 2006-10-15 Impact factor: 4.939
Authors: Jacqueline G O'Leary; S Michelle Shiller; Christopher Bellamy; Michael A Nalesnik; Hugo Kaneku; Linda W Jennings; Kumiko Isse; Paul I Terasaki; Göran B Klintmalm; Anthony J Demetris Journal: Liver Transpl Date: 2014-10 Impact factor: 5.799
Authors: K M Abu-Elmagd; G Wu; G Costa; J Lunz; L Martin; D A Koritsky; N Murase; W Irish; A Zeevi Journal: Am J Transplant Date: 2012-09-04 Impact factor: 8.086
Authors: Manon Dekeyser; Jean-Luc Taupin; Michelle Elias; Philippe Ichaï; Florence Herr; Marc Boudon; Melanie Brunel; Antonio Sa Cunha; Audrey Coilly; Faouzi Saliba; Antoine Durrbach Journal: Front Med (Lausanne) Date: 2022-08-22